我国肿瘤免疫治疗经济学评价研究现状与挑战

Research Status and Challenge of Economic Evaluation of Tumor Immunotherapy in China

随着肿瘤免疫治疗的快速发展,其经济学评价也在逐步推进。由于免疫疗法与传统治疗在作用机制、临床效果等方面均有较大差异,不同药物之间的药学特征和临床疗效也不同,因此在进行经济学评价时应做出相应的调整。以目前在我国上市的PD-1/PD-L1抑制剂为例,对国内现有药物经济学评价进行总结,分析肿瘤免疫疗法经济学评价面临的挑战,如临床数据不足、生存数据的模拟与外推尚需验证、生命质量数据来源缺失、分适应症评价的挑战,以及经济性与可负担性的矛盾等。

With the rapid development of tumor immunotherapy,its economic evaluation is also gradually advancing.There are great differences in action mechanism and clinical effect between immunotherapy and traditional therapy,and in the pharmaceutical characteristics and clinical efficacy of different drugs,so the economic evaluation should be made related adjustments.Taking the PD-1/PD-L1 inhibitors listed in China as an example,this paper summarizes the current pharmacoeconomic evaluation,and analyzes the challenges faced by the economic evaluation of tumor immunotherapy,such as lack of clinical data,simulation and extrapolation of survival data need to be verified,lack of the quality of life data source,challenge of indication evaluation,contradiction between economy and affordability,and so on.